134 related articles for article (PubMed ID: 15972684)
21. Requirement for a conserved Toll/interleukin-1 resistance domain protein in the Caenorhabditis elegans immune response.
Liberati NT; Fitzgerald KA; Kim DH; Feinbaum R; Golenbock DT; Ausubel FM
Proc Natl Acad Sci U S A; 2004 Apr; 101(17):6593-8. PubMed ID: 15123841
[TBL] [Abstract][Full Text] [Related]
22. Structural insights into the role of deleterious mutations at the dimeric interface of Toll-like receptor interferon-β related adaptor protein.
Verma S; Menon R; Sowdhamini R
Proteins; 2024 May; ():. PubMed ID: 38814166
[TBL] [Abstract][Full Text] [Related]
23. Distinct functional motifs within the IL-17 receptor regulate signal transduction and target gene expression.
Maitra A; Shen F; Hanel W; Mossman K; Tocker J; Swart D; Gaffen SL
Proc Natl Acad Sci U S A; 2007 May; 104(18):7506-11. PubMed ID: 17456598
[TBL] [Abstract][Full Text] [Related]
24. Structural Evolution of TIR-Domain Signalosomes.
Nimma S; Gu W; Maruta N; Li Y; Pan M; Saikot FK; Lim BYJ; McGuinness HY; Zaoti ZF; Li S; Desa S; Manik MK; Nanson JD; Kobe B
Front Immunol; 2021; 12():784484. PubMed ID: 34868065
[TBL] [Abstract][Full Text] [Related]
25. An AP-3-dependent pathway directs phagosome fusion with Rab8 and Rab11 vesicles involved in TLR2 signaling.
Petnicki-Ocwieja T; Sharma B; Powale U; Pathak D; Tan S; Hu LT
Traffic; 2022 Dec; 23(12):558-567. PubMed ID: 36224049
[TBL] [Abstract][Full Text] [Related]
26. Crystallization and X-ray diffraction analysis of the N-terminal domain of the Toll-like receptor signalling adaptor protein TRIF/TICAM-1.
Ullah MO; Ve T; Dkhar J; Alaidarous M; Ericsson DJ; Sweet MJ; Mansell A; Kobe B
Acta Crystallogr Sect F Struct Biol Cryst Commun; 2013 Jul; 69(Pt 7):766-70. PubMed ID: 23832204
[TBL] [Abstract][Full Text] [Related]
27. Analysis of gene-environment interactions in postnatal development of the mammalian intestine.
Rakoff-Nahoum S; Kong Y; Kleinstein SH; Subramanian S; Ahern PP; Gordon JI; Medzhitov R
Proc Natl Acad Sci U S A; 2015 Feb; 112(7):1929-36. PubMed ID: 25691701
[TBL] [Abstract][Full Text] [Related]
28. Bacterial Lipopolysaccharides Exacerbate Neurogenic Heterotopic Ossification Development.
Salga M; Samuel SG; Tseng HW; Gatin L; Girard D; Rival B; Barbier V; Bisht K; Shatunova S; Debaud C; Winkler IG; Paquereau J; Dinh A; Genêt G; Kerever S; Abback PS; Banzet S; Genêt F; Lévesque JP; Alexander KA
J Bone Miner Res; 2023 Nov; 38(11):1700-1717. PubMed ID: 37602772
[TBL] [Abstract][Full Text] [Related]
29. Formal modeling and analysis of the MAL-associated biological regulatory network: insight into cerebral malaria.
Ahmad J; Niazi U; Mansoor S; Siddique U; Bibby J
PLoS One; 2012; 7(3):e33532. PubMed ID: 22479409
[TBL] [Abstract][Full Text] [Related]
30. Peptide-Based Inhibitors of the Induced Signaling Protein Interactions: Current State and Prospects.
Toshchakov VY
Biochemistry (Mosc); 2024 May; 89(5):784-798. PubMed ID: 38880642
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of TLR4 signaling by TRAM-derived decoy peptides in vitro and in vivo.
Piao W; Vogel SN; Toshchakov VY
J Immunol; 2013 Mar; 190(5):2263-72. PubMed ID: 23345333
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of TLR2 signaling by small molecule inhibitors targeting a pocket within the TLR2 TIR domain.
Mistry P; Laird MH; Schwarz RS; Greene S; Dyson T; Snyder GA; Xiao TS; Chauhan J; Fletcher S; Toshchakov VY; MacKerell AD; Vogel SN
Proc Natl Acad Sci U S A; 2015 Apr; 112(17):5455-60. PubMed ID: 25870276
[TBL] [Abstract][Full Text] [Related]
33. A role for the adaptor proteins TRAM and TRIF in toll-like receptor 2 signaling.
Nilsen NJ; Vladimer GI; Stenvik J; Orning MP; Zeid-Kilani MV; Bugge M; Bergstroem B; Conlon J; Husebye H; Hise AG; Fitzgerald KA; Espevik T; Lien E
J Biol Chem; 2015 Feb; 290(6):3209-22. PubMed ID: 25505250
[TBL] [Abstract][Full Text] [Related]
34. TRAM is required for TLR2 endosomal signaling to type I IFN induction.
Stack J; Doyle SL; Connolly DJ; Reinert LS; O'Keeffe KM; McLoughlin RM; Paludan SR; Bowie AG
J Immunol; 2014 Dec; 193(12):6090-102. PubMed ID: 25385819
[TBL] [Abstract][Full Text] [Related]
35. Pivotal Advance: Inhibition of MyD88 dimerization and recruitment of IRAK1 and IRAK4 by a novel peptidomimetic compound.
Loiarro M; Capolunghi F; Fantò N; Gallo G; Campo S; Arseni B; Carsetti R; Carminati P; De Santis R; Ruggiero V; Sette C
J Leukoc Biol; 2007 Oct; 82(4):801-10. PubMed ID: 17548806
[TBL] [Abstract][Full Text] [Related]
36. TLR5-Derived, TIR-Interacting Decoy Peptides to Inhibit TLR Signaling.
Javmen A; Zou J; Nallar SC; Szmacinski H; Lakowicz JR; Gewirtz AT; Toshchakov VY
J Immunol; 2023 May; 210(9):1419-1427. PubMed ID: 36946775
[TBL] [Abstract][Full Text] [Related]
37. Infectious bronchitis virus inhibits activation of the TLR7 pathway, but not the TLR3 pathway.
Zhu J; Xu S; Li X; Wang J; Jiang Y; Hu W; Ruan W
Arch Virol; 2020 Sep; 165(9):2037-2043. PubMed ID: 32524263
[TBL] [Abstract][Full Text] [Related]
38. Select targeting of intracellular Toll-interleukin-1 receptor resistance domains for protection against influenza-induced disease.
Shirey KA; Lai W; Brown LJ; Blanco JCG; Beadenkopf R; Wang Y; Vogel SN; Snyder GA
Innate Immun; 2020 Jan; 26(1):26-34. PubMed ID: 31955622
[TBL] [Abstract][Full Text] [Related]
39. Targeting the TLR signalosome with TIR domain-derived cell-permeable decoy peptides: the current state and perspectives.
Toshchakov VY; Javmen A
Innate Immun; 2020 Jan; 26(1):35-47. PubMed ID: 31955621
[TBL] [Abstract][Full Text] [Related]
40. Development of a Novel Backbone Cyclic Peptide Inhibitor of the Innate Immune TLR/IL1R Signaling Protein MyD88.
Dishon S; Schumacher A; Fanous J; Talhami A; Kassis I; Karussis D; Gilon C; Hoffman A; Nussbaum G
Sci Rep; 2018 Jun; 8(1):9476. PubMed ID: 29930295
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
